AtriCure, Inc. (ATRC) has launched the cryoSPHERE MAX cryoablation probe, which enhances Cryo Nerve Block (cryoNB) therapy by reducing freeze times by 50% compared to previous models and over 30% when ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2024 investor letter. A copy of the letter can be downloaded here.

AtriCure, Inc. (NASDAQ: ATRC) recently announced the receipt of an expanded indication for the AtriClip in CE-marked countries in Europe. The product is now indicated for use in patients at ...

AQR Capital Management LLC boosted its stake in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 38.2% in the second ...

It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. Are you a shareholder? Since ATRC is currently undervalued, it may be a great time to ...

A good stock in these conditions often exhibits strong ... There's been a notable change in appetite for AtriCure, Inc. ( NASDAQ:ATRC ) shares in the week since its quarterly ...

AtriCure (Nasdaq: ATRC) announced today that it has launched the new CryoSphere Max cryoablation probe technology.

On September 17, 2024, AtriCure, Inc. (NASDAQ:ATRC) stock closed at $28.07 per share with a market capitalization of $1.367 billion. TimesSquare Capital Management U.S. Small Cap Growth Strategy ...

Investors in AtriCure Inc (Symbol: ATRC) saw new options begin trading this week, for the November 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ATRC ...

In trading on Monday, shares of AtriCure Inc (Symbol: ATRC) crossed below their 200 day moving average of $27.38, changing hands as low as $27.34 per share. AtriCure Inc shares are currently ...

AtriCure (NASDAQ:ATRC – Get Free Report ... In related news, Director Maggie Yuen sold 3,500 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average ...